Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenas Association in Type 2 Diabetes and Hypertension
NCT05144360Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of Atenas in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by EMS. Primary endpoints: Glycated hemoglobin at 120 days and Systolic blood pressure at 120 days. Planned start Aug 2022; status: withdrawn.
02
Drugs
Atenas
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT05144360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144360.